SCHEMBL526478

SCHEMBL526478

CC(C)(C=O)C(S)S

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL270229 0.69
SCHEMBL11600202 0.67
SCHEMBL5079747 0.67
SCHEMBL483574 0.67
SCHEMBL20221346 0.67
SCHEMBL195747 0.65
SCHEMBL13849138 0.65
SCHEMBL8322720 0.63
SCHEMBL9578953 0.63 TDP1 (0.30)
SCHEMBL902771 0.62

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250280857-A1 DEGRADATION-RESISTANT ALDEHYDE-CONTAINING COMPOSITIONS ZOOMESSENCE INC (US) 2025-09-11 US claimed
WO-2023215706-A1 DEGRADATION-RESISTANT ALDEHYDE-CONTAINING COMPOSITIONS ZoomEssence, Inc. (US) 2023-11-09 WO claimed
US-20260118304-A1 ODOR SIGNATURE IDENTIFICATION SYSTEM CHANDRA SHUBHAM (US) 2026-04-30 US disclosed
US-20250280857-A1 DEGRADATION-RESISTANT ALDEHYDE-CONTAINING COMPOSITIONS ZOOMESSENCE INC (US) 2025-09-11 US disclosed
US-RE49918-E1 Cytotoxic benzodiazepine derivatives IMMUNOGEN, INC. (US) 2024-04-16 US disclosed
WO-2023215706-A1 DEGRADATION-RESISTANT ALDEHYDE-CONTAINING COMPOSITIONS ZoomEssence, Inc. (US) 2023-11-09 WO disclosed
US-11505617-B2 Benzodiazepine derivatives IMMUNOGEN, INC. (US) 2022-11-22 US disclosed
CN-108727407-B Novel benzodiazepine derivatives 伊缪诺金公司 2022-01-28 CN disclosed
CN-113661172-A Cytotoxic bis-benzodiazepine derivatives and conjugates thereof with cell-binding agents for use in inhibiting abnormal cell growth or treating proliferative diseases 伊缪诺金公司 2021-11-16 CN disclosed
CN-107335061-B Cytotoxic benzodiazepine derivatives 伊缪诺金公司 2021-09-07 CN disclosed
US-20210238301-A1 NOVEL BENZODIAZEPINE DERIVATIVES IMMUNOGEN, INC. 2021-08-05 US disclosed
WO-2011023883-A1 CONJUGATES OF PYRROLO[1,4]BENZODIAZEPINE DIMERS AS ANTICANCER AGENTS SANOFI-AVENTIS (FR) 2011-03-03 WO disclosed
WO-2011001052-A1 NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-01-06 WO disclosed
US-20100203007-A1 NOVEL BENZODIAZEPINE DERIVATIVES IMMUNOGEN INC. (US) 2010-08-12 US disclosed
WO-2010091150-A1 NOVEL BENZODIAZEPINE DERIVATIVES IMMUNOGEN, INC. (US) 2010-08-12 WO disclosed
US-20090311403-A1 Method of Using Organic Compounds GIVAUDAN SA (CH) 2009-12-17 US disclosed
EP-2046147-A1 METHOD OF USING ORGANIC COMPOUNDS Givaudan SA (CH) 2009-04-15 EP disclosed
EP-1981889-A1 CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE Sanofi-Aventis (FR) 2008-10-22 EP disclosed
WO-2008011742-A1 METHOD OF USING ORGANIC COMPOUNDS GIVAUDAN SA (CH) 2008-01-31 WO disclosed
WO-2007085930-A1 CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE SANOFI-AVENTIS (FR) 2007-08-02 WO disclosed